Analysts Are Bullish on These Healthcare Stocks: Insmed (INSM), Inovio Pharmaceuticals (INO)


There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Insmed (NASDAQ:INSM), Inovio Pharmaceuticals (NASDAQ:INO) and Mesoblast Ltd (NASDAQ:MESO) with bullish sentiments.

Insmed (INSM)

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Insmed, with a price target of $43. The company’s shares closed yesterday at $18.95, close to its 52-week low of $18.93.

Fein wrote:

“Our price target of $35/share is based on: (a) $47/share, as a 35x multiple of taxed and diluted FY22 GAAP EPS of $2.80 discounted back to FY18 cat 20%; and (b) an NPV of $23/share (discount rate 12.5%, growth rate 2%). Risks to our investment thesis and target price include: (1) failure of ALIS to secure regulatory approval; and (2) failure of ALIS to achieve peak commercial revenue estimates in our model due to market size, penetration rates, and/or pricing.”

According to TipRanks.com, Fein is a 4-star analyst with an average return of 4.8% and a 44.9% success rate. Fein covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Insmed with a $42.60 average price target.

See today’s analyst top recommended stocks >>

Inovio Pharmaceuticals (INO)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Inovio Pharmaceuticals today and set a price target of $13. The company’s shares closed yesterday at $4.82.

Selvaraju said:

“Our 12-month price target is derived from a market value of the firm at $1.3B, which includes a discounted cash flow based asset value for 15% discount rate, 2% terminal growth rate and 80% probability of success. Risks include, but are not limited to: (1) failure of VGX-3100 in clinical trials; (2) failure of VGX-3100 to secure regulatory approval; (3) failure of VGX-3100 to achieve commercial success due to market size, penetration rate, and/or competition; and (4) potential failures of other pipeline candidates.”

According to TipRanks.com, Selvaraju is a 2-star analyst with an average return of 0.4% and a 42.5% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Synergy Pharmaceuticals Inc.

Currently, the analyst consensus on Inovio Pharmaceuticals is a Strong Buy with an average price target of $11, a 128.2% upside from current levels. In a report issued on September 5, Maxim Group also assigned a Buy rating to the stock with a $8 price target.

.

Mesoblast Ltd (MESO)

H.C. Wainwright analyst Jason Kolbert maintained a Buy rating on Mesoblast Ltd today and set a price target of $17. The company’s shares closed yesterday at $6.11.

According to TipRanks.com, Kolbert ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -4.6% and a 36.6% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Cytori Therapeutics Inc, Anavex Life Sciences, and Coherus Biosciences.

Currently, the analyst consensus on Mesoblast Ltd is a Strong Buy with an average price target of $18.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts